AIPT - Precision Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5500
+0.0100 (+1.85%)
As of 2:02PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.5400
Open0.5400
Bid0.5500 x 1400
Ask0.5700 x 800
Day's Range0.5300 - 0.5972
52 Week Range0.4010 - 1.5800
Volume109,330
Avg. Volume85,483
Market Cap16.874M
Beta (3Y Monthly)4.00
PE Ratio (TTM)N/A
EPS (TTM)-0.8390
Earnings DateMar 15, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Precision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner for NIIMBL Grant

    MINNEAPOLIS, May 21, 2019 -- Precision Therapeutics Inc., (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized.

  • GlobeNewswire6 days ago

    Precision Therapeutics Gains Extension for Nasdaq Compliance

    Nasdaq’s determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Bid Price Rule, and on the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

  • GlobeNewswire8 days ago

    Precision Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

    MINNEAPOLIS, May 15, 2019 -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized.

  • ACCESSWIRE8 days ago

    Precision Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 15, 2019 / Precision Therapeutics, Inc. (NASDAQ: AIPT ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 15, 2019 at 4:30 ...

  • GlobeNewswire10 days ago

    Precision Therapeutics to Report First Quarter 2019 Financial Results and Provide Company Update on Wednesday, May 15, 2019

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announces that it will report First Quarter 2019 financial results for the period ended March 31, 2019, after the market close on Wednesday, May 15, 2019. Management will host a conference call that same day at 4:30 p.m. Eastern Time to review financial results, corporate highlights, and to provide an update on developments. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Precision Therapeutics Inc., call.

  • GlobeNewswirelast month

    Precision Therapeutics’ Subsidiary Helomics and National Alopecia Areata Foundation Sign Services Agreement to Provide Next-Generation Patient Registry for Alopecia Areata Research

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced a services agreement between its wholly owned subsidiary, Helomics and the National Alopecia Areata Foundation (NAAF), which serves the community of people affected by an autoimmune skin disease called alopecia areata that results in hair loss and emotional pain, to provide a next generation patient registry to drive research into new treatments for people with this disease. “This agreement will provide NAAF with the ability to store, process and analyze specimens under one roof and in a CLIA regulated setting,” said Gerald Vardzel, president of Helomics.

  • GlobeNewswirelast month

    Precision Therapeutics’ Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Demonstration Program Grant to Support Development of Novel Cancer Treatments

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced that its wholly owned subsidiary, TumorGenesis, is participating with 48Hour Discovery (48HD), a Canadian partner, in receiving a $300,000 CAD grant through the Alberta Innovates Product Demonstration Program. The strategic collaboration will commercialize TumorGenesis’ Oncology Discovery Platform Kits, with a set of proprietary reagents from 48HD’s core technology to inform personalized treatment decisions in cancer treatments.

  • GlobeNewswirelast month

    Precision Therapeutics’ Subsidiary, Helomics® Corporation, and SpeciCare, Inc. to Study Innovative Personalized Medicine Opportunities for Cancer Patients

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced that its wholly-owned subsidiary, Helomics® Corporation (Helomics), which provides personalized medicine solutions and boutique CRO services for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SpeciCare, an innovative Georgia-based company connecting cancer patients to new treatment options only available through storing the patient’s live tumor tissue, have signed an agreement for Helomics to provide CRO services and its D-CHIP artificial intelligence (AI) platform for a functional precision medicine study sponsored by SpeciCare.

  • ACCESSWIRElast month

    Uptick Newswire Hosts Precision Therapeutics Inc. on The Stock Day Podcast to Discuss Massive Revenue Increases

    PHOENIX, AZ / ACCESSWIRE / April 11, 2019 / Uptick Newswire Stock Day Podcast welcomed Precision Therapeutics Inc. (NASDAQ: AIPT ) ("the Company"), a company with business lines that include ...

  • GlobeNewswirelast month

    Precision Therapeutics’ Subsidiary Helomics to Collaborate with Viome to Explore the Impact of the Gut Microbiome on Ovarian Cancer

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced a collaboration between its wholly owned subsidiary, Helomics, and Viome, a new kind of healthcare company transforming health at the molecular level, to study the link between the gut microbiome and ovarian cancer. The collaboration will start with a pilot study to determine what changes occur in the gut microbiome during ovarian cancer therapy and how those changes might impact outcomes.  The companies intend to apply the results from this study to develop innovative and holistic approaches to help oncologists better personalize and optimize ovarian cancer therapy. “Helomics pioneered using knowledge gained from drug response and genomic profiling of the patient’s living tumor to help individualize ovarian cancer therapy.  The collaboration with Viome is groundbreaking, generating data from the microbiome combined with our existing data and using our respective artificial intelligence (AI) platforms, to offer an innovative holistic and personalized approach to helping oncologists choose the best treatment options for patients with ovarian cancer,” commented Gerald Vardzel, president of Helomics.

  • GlobeNewswire2 months ago

    Precision Therapeutics Announces Completion of Merger with Helomics Holding Corporation

    Precision Therapeutics Inc. (AIPT) (“Precision Therapeutics” or “the Company”), today announced the completion of its merger with Helomics Holding Corporation (“Helomics”), which has become the Company’s wholly owned subsidiary, providing proprietary data driven precision medicine solutions for women’s oncology by harnessing the knowledge gained from the patient’s own living tumor using the power of  artificial intelligence (AI) technology.

  • GlobeNewswire2 months ago

    Precision Therapeutics Reports Year End 2018 Financial Results and Provides Corporate Update

    MINNEAPOLIS, April 01, 2019 -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to Women’s.

  • GlobeNewswire2 months ago

    Precision Therapeutics Inc. Announces Pricing of Public Offering of Up to $1.2 Million of Units

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced the pricing of its previously announced public offering of its common stock and warrants to purchase common stock, with anticipated gross proceeds of up to $1,200,000, before deducting placement agent fees and expenses and offering expenses payable by the Company. The Company is offering 1,500,000 units on a “best efforts” basis, with each unit consisting of one share of common stock and a warrant to purchase 0.5 of a share of common stock, at a price of $0.80 per unit. The warrants are immediately exercisable at a price of $1.00 per share of common stock and will expire on the fifth anniversary of the date of issuance.

  • GlobeNewswire2 months ago

    Precision Therapeutics Inc. Announces Proposed Public Offering of Securities

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common stock. Dawson James Securities, Inc. is acting as exclusive placement agent for the offering. The offering is being made by Precision pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective on October 4, 2016.

  • GlobeNewswire2 months ago

    Precision Therapeutics Announces Results of Special Meeting of Stockholders

    Precision Therapeutics Inc. (AIPT) (the “Company”) announced today that at a special meeting of stockholders held on March 22, 2019, the Company’s stockholders approved the Amended and Restated Agreement and Plan of Merger, dated as of October 26, 2018, by and among Precision, Helomics Acquisition, Inc. (“Merger Sub”) and Helomics Holding Corporation (“Helomics”) (the “Merger Agreement”). In addition to the Amended and Restated Agreement and Plan of Merger, stockholders approved the additional transactions proposed, including (a) the merger of Helomics with and into the Merger Sub (the “Merger”) and the issuance of shares of Precision’s common stock and Series D convertible preferred stock to Helomics’ security holders pursuant to the terms of the Merger Agreement and (b) the issuance of shares of Precision common stock and Precision warrants to the holders of Helomics notes and warrants pursuant to the Company’s exchange offer described in the Form S-4 registration statement as amended on January 24, 2019 (the “Exchange Offer”).

  • GlobeNewswire2 months ago

    Precision Therapeutics to Report Fiscal Year 2018 Financial Results and Provide Company Update on Monday, April 1, 2019

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announces that it will report Fiscal Year 2018 financial results for the period ended December 31, 2018, after the market close on Monday, April 1, 2019. Management will host a conference call that same day at 4:30 p.m. Eastern Time to review financial results, corporate highlights, and to provide an update on developments. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Precision Therapeutics Inc., call.

  • PR Newswire2 months ago

    Viome and Helomics Partner to Identify Personalized Treatment for Ovarian Cancer Patients

    SEATTLE, March 21, 2019 /PRNewswire/ -- Viome, a company transforming health through personalized nutrition based on individual biology, today announces it will collaborate with precision health leader, Helomics, to study the link between the gut microbiome and ovarian cancer. The teams will begin with a pilot study, which aims to reveal how different cancer treatments impact the gut microbiome, and if the microbiome affects effectiveness and toxicity of various cancer treatments. The hope is to transform these findings into an innovative and holistic approach to help oncologists better personalize ovarian cancer therapy.

  • GlobeNewswire2 months ago

    Precision Therapeutics Extends Exchange Offer for Helomics Notes and Warrants

    MINNEAPOLIS, March 14, 2019 -- Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced the extension of its previously announced offer (the “Exchange.

  • GlobeNewswire3 months ago

    Precision Therapeutics’ Skyline Medical Division Captures Market Share in Saudi Arabia Via New Orders While Disposable Sales Show Significant Year-Over-Year Increase

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, has entered the African continent, further expanding the company’s global presence through the sale of four STREAMWAY® units by its Saudi Arabian distributor, Sesneber International. Skyline’s goal is to get the STREAMWAY incorporated in Saudi Vision 2030 helping to develop Saudi Arabia’s healthcare infrastructure.

  • GlobeNewswire3 months ago

    Dawson James Securities Announces the Closing of Public Offering for Precision Therapeutics Inc.

    The offering is being made by Precision pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective on October 4, 2016. The securities described above will be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov.

  • GlobeNewswire3 months ago

    Precision Therapeutics Inc. Announces Pricing of Public Offering of Up to $1.26 Million of Units

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced the pricing of its previously announced public offering of its common stock and warrants to purchase common stock, with anticipated gross proceeds of up to $1.26 million, before deducting placement agent fees and expenses and offering expenses payable by the Company. The Company is offering 1,400,000 units on a “best efforts” basis, with each unit consisting of one share of common stock and a warrant to purchase 0.5 of a share of common stock, at a price of $0.90 per unit. The warrants are immediately exercisable at a price of $1.00 per share of common stock and will expire on the fifth anniversary of the date of issuance.

  • GlobeNewswire3 months ago

    Precision Therapeutics Inc. is Excited to Announce a Special Meeting of Stockholders and Commencement of Registered Exchange Offer

    Precision Therapeutics Inc. (AIPT) (“Precision”) today announced the effectiveness of its Form S-4 registration statement, the establishment of the date of its special meeting of stockholders in connection with the proposed business combination of Precision and Helomics Holding Corporation (“Helomics” and such business combination of Precision and Helomics, the “Proposed Merger”), and information regarding its related registered Exchange Offer described below. A special meeting of the stockholders of Precision will be held at 9:30 a.m. (local time) on March 22, 2019 at the offices of Precision’s counsel, Maslon LLP, at 3300 Wells Fargo Center, 90 South Seventh Street, Minneapolis, Minnesota 55402, unless postponed or adjourned to a later date.

  • GlobeNewswire3 months ago

    Precision Therapeutics’ Skyline Medical Division Expands Presence in Australia with Three New STREAMWAY Systems at Wangaratta Hospital in Victoria

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announces its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY® System for automated, direct-to-drain medical fluid disposal, has received an order from its Australian distributor for three STREAMWAY system units to be placed in a “center of excellence” in an emerging orthopedic department at Wangaratta Hospital in Victoria, Australia. The three units are a significant addition to Skyline’s presence in Australia and are placed in conjunction with its Australian distributor, Device Technologies, AU (https://www.device.com.au). “We are particularly pleased to be introducing the STREAMWAY system to the Victoria market, as it represents Australia’s second-most densely-populated region.  More importantly, the Wangaratta Hospital will serve as a center of excellence through which Device Technologies can effectively demonstrate the system to potential customers in a real-world application,” commented Dr. Carl Schwartz, chief executive officer of Precision Therapeutics.

  • GlobeNewswire4 months ago

    Precision Therapeutics’ TumorGenesis Division Isolates Discovery Biomarkers for Thyroid Cancer Cell Types, Initiating Its Proprietary Process for New Drug Development Via Patient-Derived Tumor Models

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announces its TumorGenesis subsidiary has identified three thyroid cancer cell types and has isolated the discovery biomarkers.  The company will utilize this discovery to further develop its proprietary TumorGenesis system for Cancer Cell Capture and Culture, which permits screening of drugs against the cancers cells.  The TumorGenesis system enables cells grown outside the body to behave as though they were present in a patient, potentially making the drug screening process more predictive. The TumorGenesis system, which the Company believes represents a paradigm shift in the way drug discovery is conducted, relies on the ability to grow tumors outside the body that will have the same genotype as a cancer mutation.  This methodology will allow pharmaceutical developers to create therapies that are unique to a particular patient’s tumor.  The biomarkers identified by TumorGenesis for these types of thyroid cancer involve the sequencing of the peptides that reside on the surface of the tumor cell.